Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.

Authors: Thomas Powles, Neal D. Shore, Jens Bedke, Matthew D. Galsky, Joan Palou, Hailong Hu, Evanguelos Xylinas, Javier Puente, Jason Hafron, Michele Lodde, Alketa Hamzaj, Julia Brinkmann, Anna Maria Calella, Rossano Cesari, Jennifer Vermette, Caimiao Wei, Gary D. Steinberg

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.4517

Source: Full article

---

Abstract

4517